tbuckley/cabot-search huggingface dataset:
Abstract 3036: Basal stem cells contribute to squamous cell carcinomas in the oral cavity
Authors: Xiao-Han Tang, Theresa Scognamiglio, Lorraine Gudas
Journal: Cancer Research (2014)

Abstract The cells of origin of oral cavity squamous cell carcinoma (OCSCC) are unknown. We used a cell lineage tracing approach (adult K14-CreERTAM; ROSA 26 mice transiently treated with tamoxifen) to identify and track normal epithelial stem cells (SCs) in mouse tongues by X-gal staining and to determine if these cells become neoplastically transformed by treatment with a carcinogen, 4-nitroquinoline 1-oxide (4-NQO). Here we show that in normal tongue epithelia, X-gal(+) cells formed thin columns throughout the entire epithelium 12 weeks after tamoxifen treatment, indicating that the basal layer contains long lived SCs that produce progeny by asymmetric division to maintain homeostasis. Carcinogen treatment results in a ∼ 10 fold reduction in the total number of X-gal(+) clonal cell populations and horizontal expansion of X-gal(+) clonal cell columns, a pattern consistent with symmetric division of some SCs. Finally, X-gal(+) SCs are present in papillomas and invasive OCSCCs, and these long-lived X-gal(+) SCs are the cells of origin of these tumors. Moreover, the resulting 4-NQO induced tumors are multi-clonal. These findings provide insights into the identity of the initiating cells of oral cancer. Citation Format: Xiao-Han Tang, Theresa Scognamiglio, Lorraine Gudas. Basal stem cells contribute to squamous cell carcinomas in the oral cavity. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 3036. doi:10.1158/1538-7445.AM2014-3036
Abstract 904: EGFR expression predicts recurrence in patients undergoing adjuvant chemotherapy for advanced bladder cancer
Authors: Ahmed Mansour, Mona Abdulreheem, Mamdouh Elsherbeeny, Mohammed Sultan, Ahmed Shokeir, Ahmed Mosbah, Hassan Abol-Enein, Taeeun Park, Hyung Kim, Jayoung Kim
Journal: Cancer Research (2014)

Abstract Epidermal growth factor receptor (EGFR) overexpression has been associated with bladder cancer progression and poor clinical outcomes. In vivo studies have linked EGFR subcellular trafficking and chemo-resistance to cisplatin-based protocols in other tumor types. This has not been studied in the clinical adjuvant setting in bladder cancer. In this study, we aimed to investigate the prognostic significance of EGFR expression in patients receiving adjuvant chemotherapy following radical cystectomy for advanced bladder cancer. Mansoura Urology and Nephrology Center database was reviewed. Patients treated with radical cystectomy and thereafter completed adjuvant chemotherapy for adverse pathological features or node positive diseases were identified. Patients who underwent palliative cystectomy, those with histological diagnosis other than pure transitional cell carcinoma and patients who received adjuvant radiotherapy were excluded. Immunohistochemical analysis for EGFR expression was performed on archived bladder specimens. The relationship of EGFR expression and clinical outcomes was assessed. In vitro studies were performed to determine whether EGFR expression associates with resistance to chemotherapeutic reagents. The study included 58 patients. Mean age was 57 years. All patients had pathologic stage T2 or greater. Majority of patients had node positive disease (n=53, 91%). Mean follow up was 26.61 months. EGFR was overexpressed in 25 cystectomy specimens (43%). Kaplan Meyer analysis revealed that EGFR over-expression significantly correlated with disease recurrence (p=0.021). Cox proportional hazard modeling identified EGFR overexpression as an independent predictor for disease recurrence (p=0.04). In vitro functional analysis demonstrated that EGFR expression level altered response to cisplatin-induced apoptosis, and that inhibition of EGFR enhanced sensitization of bladder cancer cells to cisplatin-induced apoptosis. In summary, our findings suggest that EGFR overexpression is associated with disease recurrence following adjuvant chemotherapy for advanced bladder cancer. EGFR status may help predict prognosis and select patients for adjuvant chemotherapy. Citation Format: Ahmed Mansour, Mona Abdulreheem, Mamdouh Elsherbeeny, Mohammed Sultan, Ahmed Shokeir, Ahmed Mosbah, Hassan Abol-Enein, Taeeun Park, Hyung Kim, Jayoung Kim. EGFR expression predicts recurrence in patients undergoing adjuvant chemotherapy for advanced bladder cancer. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 904. doi:10.1158/1538-7445.AM2014-904
Immunohistochemical demonstration of carcinoembryonic antigen and related antigens in various cutaneous keratinous neoplasms and verruca vulgaris
Authors: None Egawa, None Honda, None Ono, None Kuroki
Journal: British Journal of Dermatology (1998)

Carcinoembryonic antigen (CEA), which is a well-known marker for the normal sweat gland apparatus and its neoplasms in the skin, was recently demonstrated in sebaceous neoplasms. The aim of this study was to examine the expression of CEA and related antigens in the other cutaneous keratinous neoplasms and verruca vulgaris. Normal adult skin, squamous cell carcinoma (SCC), senile keratosis, Bowen's disease, basal cell carcinoma (BCC), seborrhoeic keratosis and verruca vulgaris were stained immunohistochemically with a panel of monoclonal and polyclonal antibodies that recognize different epitopes of CEA and related molecules. Localization of the antigens was compared with that of involucrin and proliferating cell nuclear antigen. The strongest expression of CEA-related antigens, other than non-specific cross-reacting antigen (NCA) -50/90, was seen in SCC and verruca vulgaris, while no detectable expression was seen in BCC. Senile keratosis, Bowen's disease and seborrhoeic keratosis showed the predominance of the CEA-related antigens over CEA weakly expressed. Strong expression of both CEA and NCA-50/90 was seen only in SCC. All the expressions were limited to the cells situated in the upper epidermal cell layers of the tumours, at the centre of tumour islands in SCC and along the pseudohorn cysts in seborrhoeic keratosis, where involucrin was coexpressed. We suggest that CEA and related antigens are not only markers for sweat gland differentiation in the skin, as currently accepted, but are also expressed in various cutaneous keratinous neoplasms and verruca vulgaris. The expression may correlate with the terminal differentiation of the tumour cells, the strong coexpression of CEA and NCA-50/90 may correlate with the malignant potential of the tumour types, and the mechanisms that control the expression of CEA and related antigens in the neoplasms may be similar to those operative in verruca vulgaris.
Abstract 15048: Circulating microRNAs as Diagnostic and Prognostic Markers for Heart Failure
Authors: Lee Lee Wong, Jia Yuen Lim, Lihan Zhou, Ruiyang Zou, Michelle M.Y. Chan, Carolyn S.P. Lam, Heng-Phon Too, Arthur M Richards
Journal: Circulation (2014)

Introduction:  MicroRNAs have recently emerged as central players in many diseases. Their profound role in regulation of cardiac remodeling and the evolution of heart failure (HF) suggests that circulating microRNAs may have diagnostic and prognostic value. Their potential diagnostic utility in HF and/or in distinguishing HF with reduced (HFREF) versus preserved (HFPEF) left ventricular ejection fraction is not fully defined.   Hypotheses:  (1) HF and the two phenotypes -HFREF and HFPEF are associated with distinct circulating microRNA signatures. (2) Plasma microRNA profiles may be prognostic in HF.   Methods and results:  MicroRNA profiling was performed on plasma from 162 healthy control, 135 HFREF (with EF 50%). Eighty two microRNAs were differentially dysregulated to allow distinguishing of HF from controls with AUC>0.65, p 0.60, p 0.90. Furthermore, microRNAs scoring complemented NT-proBNP results by classifying NT-proBNP-assay false positive and negative results with >90% accuracy. A selected panel of microRNAs was prognostic by unadjusted Kaplan-Meier survival curve analysis. The 2 year survival rate for those with high microRNAs expression (better survival) was 95% versus 75% with low microRNA expression (p   Conclusion:  This study shows specific microRNA signatures derived from plasma may distinguish HF from controls and HFREF from HFPEF. We also identified a panel of microRNAs as a potential prognostic tool for mortality in HF. To our knowledge, this is the largest cohort study to undertake a comparison of microRNA of HF and the two phenotypes.
Lesson of the week: Interpretation of rubella serology in pregnancy---pitfalls and problems
Authors: Jennifer M Best, Siobhan O'Shea, Graham Tipples, Nicholas Davies, Saleh M Al-Khusaiby, Amanda Krause, Louise M Hesketh, Li Jin, Gisela Enders
Journal: BMJ (2002)

Clinical and laboratory expertise is essenrial for evaluating rubella specific IgM test results in pregnancy
Abstract 17220: Effects of the Oral Adsorbent of AST-120 in Patients with both Chronic Heart Failure and Chronic Kidney Disease
Authors: Miki Imazu, Masanori Asakura, Takuya Hasegawa, Hiroshi Asanuma, Shin Ito, Atsushi Nakano, Akira Funada, Yasuo Sugano, Takahiro Ohara, Hideaki Kanzaki, Hiroyuki Takahama, Toshisuke Morita, Toshihisa Anzai, Masafumi Kitakaze
Journal: Circulation (2014)

Background: One of uremic toxins, indoxyl sulfate (IS) is related to the progression of chronic kidney disease (CKD) and the worse cardiovascular outcomes. We have previously reported the relationship between IS levels and the severity of chronic heart failure (CHF), but the question arises as to whether the treatment of uremic toxin is beneficial in patients with CHF. This study aimed to elucidate whether the treatment with the oral adsorbent which reduces uremic toxin improved the cardiac function of the patients with CHF. Methods: First of all, we retrospectively enrolled 49 patients with both CHF and stage ≤3 CKD in our institute compared with the healthy subjects without CHF or CKD in the resident cohort study of Arita. Secondly, we retrospectively enrolled 16 CHF outpatients with stage 3-5 CKD. They were treated with and without the oral adsorbent of AST-120 for one year termed as the treatment and control groups, respectively. We underwent both blood test and echocardiography before and after the treatment. Results: First of all, among 49 patients in CHF patients, plasma IS levels increased to 1.38 ± 0.84 μg/ml from the value of 0.08 ± 0.06 μg/ml in Arita-cho as a community-living matched with gender and eGFR of CHF patients. We found both fractional shortening (FS) and E/e’, an index of diastolic function were decreased (25.0 ± 12.7%) and increased (13.7 ± 7.5), respectively in CHF patients compared with the value of FS and E/e’ in Arita-cho (FS: 41.8 ± 8.3%, E/e’: 8.8 ± 2.1). Secondly, in the treatment group, the plasma IS levels and the serum creatinine and brain natriuretic peptide levels decreased (1.40 ± 0.17 to 0.92 ± 0.15 μg/ml; p&lt;0.05, 1.91 ± 0.16 to 1.67 ± 0.12 mg/dl; p&lt;0.05, 352 ± 57 to 244 ± 49 pg/ml; p&lt;0.05, respectively) and both FS and E/e’ were improved following the treatment with AST-120 (28.8 ± 2.8 to 32.9 ± 2.6%; p&lt;0.05, 18.0 ± 2.0 to 11.8 ± 1.0; p&lt;0.05). However, these parameters did not change in the control group. Conclusions: The treatment to decrease the blood levels of uremic toxins improved not only renal dysfunction but cardiac systolic and diastolic dysfunction in patients with chronic heart failure. Oral adsorbents might be a new treatment of heart failure especially with diastolic dysfunction.
Abstract 12731: Severity of LV Diastolic Stiffness as Assessed by the Diastolic Wall Strain Index is Associated With Worse Outcomes in Heart Failure With Preserved Ejection Fraction
Authors: Tomohito Ohtani, Kazuhiro Yamamoto, Shannon M Dunlay, Susan A Weston, Veronique L Roger, Margaret M Redfield
Journal: Circulation (2010)

Background: Increased LV diastolic stiffness is thought to contribute to the pathophysiology of heart failure with preserved EF (HFpEF). Currently, diastolic stiffness is inferred from Doppler indi...
Abstract 1764: Rapid Induction of Percutaneous Cardiopulmonary Bypass Significantly Improves Neurological Function in Patients with Out-of-Hospital Cardiogenic Cardiopulmonary Arrest Refractory to Advanced Cardiovascular Life Support
Authors: Hitoshi Kano, Kei Yamazaki, Midori Nakajima, Akio Endou, Katsutoshi Sano, Toshinao Matsui, Shinji Uegaki, Naomi Henzan, Masaki Okada, Hiroshi Makise, Yasumi Igarashi, Noriyoshi Katou, Masaki Togashi, Tomoyuki Satou
Journal: Circulation (2006)

Objectives: Percutaneous cardiopulmonary bypass (PCPB) is a powerful tool for rescuing the emergency patients (pts) with out-of-hospital cardiogenic cardiac arrest (OHCCA), who are not responding t...
Efficacy of targeted intraoperative radiotherapy (Targit) boost after breast-conserving surgery: Updated results
Authors: J. S. Vaidya, M. Baum, J. S. Tobias, S. Massarut, F. K. Wenz, B. Hilaris, T. Corica, U. Kraus-Tiefenbacher, M. Roncadin, M. Keshtgar, C. Saunders, D. Joseph
Journal: Journal of Clinical Oncology (2008)

565 Background: In 1998 we started a phase II study of TARGeted Intraoperative radioTherapy (TARGIT) using the Intrabeam system. We present the updated results of this first group of breast cancer patients treated with breast-conserving surgery where Targit was used as a boost to the tumor bed. Methods: We treated 301 cancers in 300 patients undergoing breast- conserving surgery with no other selection criteria. 97 patients were younger than 51 years, 57% of cancers were between 1 to 2cm, (21% > 2cm), 29% had a grade 3 tumor and 29% were node positive. After lumpectomy, 20Gy was delivered intraoperatively using 50 kV X-rays to the surface of the tumor bed. Postoperative external beam radiotherapy excluded the usual boost. One patient from the original series (Vaidya JS, Baum M, Tobias JS et al. Targeted intraoperative radiotherapy [TARGIT] yields very low recurrence rates when given as a boost. Int J Rad Oncol Biol Phys 66:1335–1338, 2006) did not receive external beam radiotherapy and is now excluded, but remains recurrence free after 51 months. Results: The treatment was well tolerated. At median follow-up of 49 months, 5 patients (1.66%) had local recurrence. The Kaplan-Meier estimate of local recurrence at 5 years is 1.52% (SE=0.76%). This compares very favorably with the 4.3% recurrence rate in boosted patients from the EORTC boost study in which only 8.1% patients were node-positive, as opposed to 29% in our series. Conclusions: It appears that lumpectomy and Targit boost combined with external beam radiotherapy results in an exceptionally low local recurrence rate. This could be attributed to both accurate geometry of the boost and timeliness of the treatment. Irradiation of the tumour bed at the time of surgery might also provide a favorable effect on the micro-environment of any residual disease (Belletti B, Vaidya JS, D'Andrea S, et al. Targeted intraoperative radiotherapy [TARGIT] impairs surgical wound-stimulated breast cancer cell proliferation and invasion. Clin Cancer Res [in press], 2008). These results suggest that not only could Targit be safely used as a boost, but that it is likely to be superior to conventional external boost. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Carl Zeiss Carl Zeiss Carl Zeiss Carl Zeiss
Primary cutaneous Ewing sarcoma: a systematic review focused on treatment and outcome
Authors: M. Delaplace, C. Lhommet, G. de Pinieux, B. Vergier, A. de Muret, L. Machet
Journal: British Journal of Dermatology (2011)

Despite intensive treatment, the overall prognosis of Ewing sarcoma of the bone remains poor. Primary cutaneous Ewing sarcoma very rarely occurs and the prognosis has been reported to be better in some small series. All cases of Ewing sarcoma are currently treated in the same way, regardless of their location.To determine whether Ewing sarcoma of the bone and primary cutaneous Ewing sarcoma are different in terms of epidemiology and prognosis.A systematic review of the literature was carried out using the keywords 'cutaneous Ewing's sarcoma', 'primary Ewing's sarcoma of skin' and 'primary neuroectodermal tumour and skin' in the Medline database. Series of five or more cases were included.Six series met the inclusion criteria, making a total of 61 patients. Median age at diagnosis was 17 years and 33% were male. The median size of the tumour was 2·3 cm. The treatment consisted of surgery in all cases, adjuvant multiagent chemotherapy in 69% of cases, adjuvant chemoradiotherapy in 38% of cases and adjuvant radiotherapy without adjuvant chemotherapy in 3% of cases. Six patients developed metastases, four of whom died. The overall survival was 93% and the 10-year probability of survival was estimated at 91% (95% confidence interval 83-100).This systematic review demonstrated epidemiological and prognostic differences between Ewing sarcoma of the bone and primary cutaneous Ewing sarcoma. Primary cutaneous Ewing sarcoma has a female predominance, occurs at a later age, but, more importantly, has a better outcome. Multimodal therapy for Ewing sarcoma is associated with immediate and long-term morbidity and mortality. Although the size of our study does not allow a definitive conclusion about treatment modalities, we suggest that a less toxic approach compared with conventional treatment should be investigated in primary cutaneous Ewing sarcoma.
Aging Prisoners Stressing Health Care System
Authors: Mike Mitka
Journal: JAMA (2004)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Allergen‐specific IgE as a biomarker of exposure plus sensitization in inner‐city adolescents with asthma
Authors: E. C. Matsui, H. A. Sampson, H. T. Bahnson, R. S. Gruchalla, J. A. Pongracic, S. J. Teach, P. J. Gergen, G. R. Bloomberg, J. F. Chmiel, A. H. Liu, M. Kattan, C. A. Sorkness, S. F. Steinbach, R. E. Story, C. M. Visness
Journal: Allergy (2010)

To cite this article: Matsui EC, Sampson HA, Bahnson HT, Gruchalla RS, Pongracic JA, Teach SJ, Gergen PJ, Bloomberg GR, Chmiel JF, Liu AH, Kattan M, Sorkness CA, Steinbach SF, Story RE, Visness CM, on behalf of the Inner‐city Asthma Consortium. Allergen‐specific IgE as a biomarker of exposure plus sensitization in inner‐city adolescents with asthma. Allergy 2010; 65 : 1414–1422. Abstract Background: Relationships among allergen‐specific IgE levels, allergen exposure and asthma severity are poorly understood since sensitization has previously been evaluated as a dichotomous, rather than continuous characteristic. Methods: Five hundred and forty‐six inner‐city adolescents enrolled in the Asthma Control Evaluation study underwent exhaled nitric oxide (FE NO ) measurement, lung function testing, and completion of a questionnaire. Allergen‐specific IgE levels and blood eosinophils were quantified. Dust samples were collected from the participants’ bedrooms for quantification of allergen concentrations. Participants were followed for 12 months and clinical outcomes were tracked. Results: Among sensitized participants, allergen‐specific IgE levels were correlated with the corresponding settled dust allergen levels for cockroach, dust mite, and mouse ( r = 0.38, 0.34, 0.19, respectively; P &lt; 0.0001 for cockroach and dust mite and P = 0.03 for mouse), but not cat ( r = −0.02, P = 0.71). Higher cockroach‐, mite‐, mouse‐, and cat‐specific IgE levels were associated with higher FE NO concentrations, poorer lung function, and higher blood eosinophils. Higher cat, dust mite, and mouse allergen‐specific IgE levels were also associated with an increasing risk of exacerbations or hospitalization. Conclusions: Allergen‐specific IgE levels were correlated with allergen exposure among sensitized participants, except for cat. Allergen‐specific IgE levels were also associated with more severe asthma across a range of clinical and biologic markers. Adjusting for exposure did not provide additional predictive value, suggesting that higher allergen‐specific IgE levels may be indicative of both higher exposure and a greater degree of sensitization, which in turn may result in greater asthma severity.
Peyroni Hastalığının Tedavisinde Vücut Dışından Şok Dalga Tedavisini Değerlendiren İlk Prospektif, Randomize, Çift-Kör, Plasebo-Kontrollü Klinik Bir Çalışma
Authors: Alessandro Palmieri, Ciro Imbimbo, Nicola Longo, Ferdinando Fusco, Paolo Verze, Francesco Mangiapia, Massimiliano Creta, Vincenzo Mirone
Journal: European Urology (2009)
Abstract 3532: Lipoprotein-Associated Phospholipase A2 and High Sensitivity C-Reactive Protein Levels and the Prediction of Cardiovascular Risk Among Coronary Artery Disease Patients With Differing Clinical Presentations
Authors: Heidi T May, Jeffrey L Anderson, Benjamin D Horne, Robert R Pearson, Robert L Wolfert, Matthew J Kolek, John F Carlquist, Richard B Lanman, Brianna S Ronnow, Joseph B Muhlestein
Journal: Circulation (2007)
Long-term outcome of severe chronic plaque psoriasis following treatment with high-dose topical calcipotriol
Authors: None Bleiker, None Bourke, None Mumford, None Hutchinson
Journal: British Journal of Dermatology (1998)

We have previously reported the effectiveness of high-dose calcipotriol in extensive psoriasis. We now report the long-term outcome in patients following this treatment. Twenty-eight patients with severe psoriasis were treated as in-patients with high-dose topical calcipotriol for 2 weeks. There was a mean reduction in the psoriasis area and severity index of 65%. Sixty-nine per cent were controlled for 3 months and 42% for 6 months. The relapse rate was comparable with that following Ingram's regimen, the in-patient stay was shorter and the treatment more acceptable. Careful monitoring of calcium homeostasis is mandatory.
Mutations in TGIF cause holoprosencephaly and link NODAL signalling to human neural axis determination
Authors: Karen W. Gripp, David Wotton, Michael C. Edwards, Erich Roessler, Lesley Ades, Peter Meinecke, Antonio Richieri-Costa, Elaine H. Zackai, Joan Massagué, Maximilian Muenke, Stephen J. Elledge
Journal: Nature Genetics (2000)